Literature DB >> 30940552

Smaller-Diameter Covered Transjugular Intrahepatic Portosystemic Shunt Stents Are Associated With Increased Survival.

Jonel Trebicka1, Diana Bastgen2, Jonathan Byrtus3, Michael Praktiknjo2, Sophia Terstiegen2, Carsten Meyer4, Daniel Thomas4, Rolf Fimmers5, Markus Treitl6, Wulf Euringer7, Tilman Sauerbruch2, Martin Rössle7.   

Abstract

BACKGROUND & AIMS: We studied the effects of diameter of covered, self-expandable, nitinol stents on survival times of patients with a transjugular intrahepatic portosystemic shunt (TIPS).
METHODS: We collected data from 185 patients (median age, 55 y; 30% female) who received a covered nitinol stent, from February 2006 through September 2010, using the online multicenter German TIPS registry. TIPS were given to 107 patients for refractory ascites and to 78 patients for variceal bleeding. Patients at risk of hepatic encephalopathy (owing to advanced age, prior episodes) or liver failure (bilirubin level, >3 mg/dL), and bleeding patients receiving variceal embolization at TIPS, received 8-mm stents (n = 53). The remaining patients received 10-mm stents (n = 132). Eighty-one of the 10-mm stents were underdilated using 8-mm dilation balloons. Clinical and biochemical data were collected after TIPS placement at 1 month, 3 months, 6 months, 9 months, 1 year, and thereafter every 3 to 6 months. Groups were compared using propensity score analysis.
RESULTS: Patients who received 8-mm stents survived significantly longer (34 ± 26 mo) than patients who received 10-mm stents (18 ± 19 mo), regardless of whether they were fully dilated or underdilated. When we compared 10-mm stents with or without underdilation, we found that a significantly higher proportion of patients who received underdilated stents survived for 1 month after TIPS placement (95% vs 84%; P = .03), but not for 3 months (P = .10). In multivariate analysis, 1-year mortality correlated with full dilation of the stent to 10 mm (hazard ratio [HR], 2.0; 95% CI, 1.1-3.5) and with serum creatinine concentration at baseline (HR, 1.5; 95% CI, 1.0-1.7). Five-year mortality was associated with use of the 10-mm stents (HR, 1.8; 95% CI, 1.4-2.7) and baseline concentration of creatinine (HR, 1.3; 95% CI, 1.1-1.6).
CONCLUSIONS: A smaller stent (nominal diameter of 8 mm, but not underdilation of a 10-mm stent) is associated with a prolonged survival compared with 10-mm stents, independent of liver-specific prognostic criteria.
Copyright © 2019 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cirrhosis; Comparison; Covered; Portal Hypertension

Mesh:

Year:  2019        PMID: 30940552     DOI: 10.1016/j.cgh.2019.03.042

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  20 in total

Review 1.  Imaging-guided interventions modulating portal venous flow: Evidence and controversies.

Authors:  Roberto Cannella; Lambros Tselikas; Fréderic Douane; François Cauchy; Pierre-Emmanuel Rautou; Rafael Duran; Maxime Ronot
Journal:  JHEP Rep       Date:  2022-04-04

2.  CT-based radiomics model for preoperative prediction of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt.

Authors:  Sihang Cheng; Xiang Yu; Xinyue Chen; Zhengyu Jin; Huadan Xue; Zhiwei Wang; Ping Xie
Journal:  Br J Radiol       Date:  2022-01-31       Impact factor: 3.629

Review 3.  Where does TIPS fit in the management of patients with cirrhosis?

Authors:  Juan Carlos García-Pagán; Saad Saffo; Mattias Mandorfer; Guadalupe Garcia-Tsao
Journal:  JHEP Rep       Date:  2020-05-23

Review 4.  Transjugular Intrahepatic Portosystemic Shunt Placement for Portal Hypertension: Meta-Analysis of Safety and Efficacy of 8 mm vs. 10 mm Stents.

Authors:  Jiangtao Liu; Eric Paul Wehrenberg-Klee; Emily D Bethea; Raul N Uppot; Kei Yamada; Suvranu Ganguli
Journal:  Gastroenterol Res Pract       Date:  2020-10-17       Impact factor: 2.260

5.  Prediction of overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt treatment: a cohort study.

Authors:  Yang Yang; Sirui Fu; Bin Cao; Kenan Hao; Yong Li; Jianwen Huang; Wenfeng Shi; Chongyang Duan; Xiao Bai; Kai Tang; Shirui Yang; Xiaofeng He; Ligong Lu
Journal:  Hepatol Int       Date:  2021-05-11       Impact factor: 6.047

6.  Guidelines on the management of ascites in cirrhosis.

Authors:  Guruprasad P Aithal; Naaventhan Palaniyappan; Louise China; Suvi Härmälä; Lucia Macken; Jennifer M Ryan; Emilie A Wilkes; Kevin Moore; Joanna A Leithead; Peter C Hayes; Alastair J O'Brien; Sumita Verma
Journal:  Gut       Date:  2020-10-16       Impact factor: 23.059

7.  Potential Benefits of Underdilation of 8-mm Covered Stent in Transjugular Intrahepatic Portosystemic Shunt Creation.

Authors:  Jiacheng Liu; Jinqiang Ma; Chen Zhou; Chongtu Yang; Songjiang Huang; Qin Shi; Bin Xiong
Journal:  Clin Transl Gastroenterol       Date:  2021-06-18       Impact factor: 4.488

Review 8.  Transjugular intrahepatic portosystemic shunt in cirrhosis: An exhaustive critical update.

Authors:  Sasidharan Rajesh; Tom George; Cyriac Abby Philips; Rizwan Ahamed; Sandeep Kumbar; Narain Mohan; Meera Mohanan; Philip Augustine
Journal:  World J Gastroenterol       Date:  2020-10-07       Impact factor: 5.742

Review 9.  North American Practice-Based Recommendations for Transjugular Intrahepatic Portosystemic Shunts in Portal Hypertension.

Authors:  Justin R Boike; Bartley G Thornburg; Sumeet K Asrani; Michael B Fallon; Brett E Fortune; Manhal J Izzy; Elizabeth C Verna; Juan G Abraldes; Andrew S Allegretti; Jasmohan S Bajaj; Scott W Biggins; Michael D Darcy; Maryjane A Farr; Khashayar Farsad; Guadalupe Garcia-Tsao; Shelley A Hall; Caroline C Jadlowiec; Michael J Krowka; Jeanne Laberge; Edward W Lee; David C Mulligan; Mitra K Nadim; Patrick G Northup; Riad Salem; Joseph J Shatzel; Cathryn J Shaw; Douglas A Simonetto; Jonathan Susman; K Pallav Kolli; Lisa B VanWagner
Journal:  Clin Gastroenterol Hepatol       Date:  2021-07-15       Impact factor: 13.576

10.  Transjugular intrahepatic portosystemic stent-shunt in the management of portal hypertension.

Authors:  Dhiraj Tripathi; Adrian J Stanley; Peter C Hayes; Simon Travis; Matthew J Armstrong; Emmanuel A Tsochatzis; Ian A Rowe; Nicholas Roslund; Hamish Ireland; Mandy Lomax; Joanne A Leithead; Homoyon Mehrzad; Richard J Aspinall; Joanne McDonagh; David Patch
Journal:  Gut       Date:  2020-02-29       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.